Paion AG (FRA:PA8K)

Germany flag Germany · Delayed Price · Currency is EUR
0.0120
0.00 (0.00%)
At close: Dec 3, 2025
33.33%
Market Cap 85.60K
Revenue (ttm) 14.81M
Net Income (ttm) -19.86M
Shares Out 7.13M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,138
Average Volume 245
Open 0.0120
Previous Close 0.0120
Day's Range 0.0120 - 0.0120
52-Week Range 0.0002 - 0.0600
Beta 1.64
RSI 46.84
Earnings Date Aug 29, 2025

About Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distribu... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 64
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PA8K
Full Company Profile

Financial Performance

In 2022, Paion AG's revenue was 33.25 million, an increase of 366.44% compared to the previous year's 7.13 million. Losses were -579,000, -97.34% less than in 2021.

Financial Statements

News

There is no news available yet.